Ge Long Hui·2026-03-31 15:27Core Viewpoint - China Biopharmaceutical reported a 10.3% year-on-year revenue growth to 31.83 billion yuan in 2025, with innovative product revenue increasing by 26.2% to 1.52 billion yuan, accounting for 47.8% of total revenue [1] Group 1: Financial Performance - The adjusted net profit attributable to shareholders grew by 31.4% year-on-year to 4.54 billion yuan, and even excluding the dividend from Sinovac Biotech, the adjusted net profit still increased by 15% [1] - The company's 2025 revenue was 7.4% lower than the analysts' expectations and 3.9% lower than Bloomberg consensus, while the adjusted net profit fell short by 27.5% and 9.0% respectively, primarily due to the milestone payment of 300 million USD from Merck not being accounted for as expected [1] Group 2: Innovation and Product Pipeline - In 2025, the company achieved approvals for four innovative products, including the world's first CDK2/4/6 inhibitor, Kimosir, and the first high-selectivity HER2 TKI, Zongaitini [2] - The company has a large pipeline of innovative drugs, with 39 in clinical stages in the oncology field, including several assets with global first-in-class or best-in-class potential [2] - The management aims to obtain approvals for nearly 20 innovative products and new indications between 2026 and 2028 [2] Group 3: Strategic Collaborations and Acquisitions - In February 2026, the company entered a global exclusive licensing agreement with Sanofi for 135 million USD upfront, along with milestone payments and sales royalties for the global development and commercialization rights of Roflumilast [3] - The company completed two significant acquisitions: a full acquisition of Lixin Pharmaceutical for up to 950 million USD in July 2025 and a 1.2 billion yuan acquisition of Hejiya in January 2026 [3] - The management indicated that external licensing will be a core objective for future business development, with expectations for continued successful licensing agreements [3] Group 4: Future Outlook - The company is set to disclose multiple important clinical data in 2026, including Phase I data for various innovative treatments at major conferences [3] - The target price based on DCF has been adjusted from 9.40 HKD to 8.70 HKD, reflecting a downward revision in expectations for non-business development revenue [4] - Revenue growth projections for 2026E/27E/28E are 13.5%/7.1%/9.2%, with adjusted net profit growth of 5.4%/8.3%/10.5% [4]